CNCR logo

CNCR ETF

Profile

Name:

Range Cancer Therapeutics Index ETF

Assets under management:

$13 M

Expense ratio:

0.79%

Inception date:

14 October 2015

Website:

-

Last ex-dividend date:

29 December 2021

Next ex-dividend date:

N/A

Description:

The CNCR ETF is an exchange-traded fund that focuses on companies involved in cancer research and treatment. It aims to provide investors with exposure to the growing healthcare sector, particularly in oncology, by investing in firms developing innovative therapies and technologies for cancer care.
Name
Weight
3.59 %
REPL logo
Replimune(REPL)
3.54 %
ZYME logo
Zymeworks(ZYME)
3.45 %
ARGX logo
argenx SE(ARGX)
3.42 %
3.42 %
3.39 %
XNCR logo
Xencor(XNCR)
3.37 %

Holding types

Countries

Sectors

Analyst ratings

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series
4 Solid ETFs Under $20 for Your Portfolio
4 Solid ETFs Under $20 for Your Portfolio
4 Solid ETFs Under $20 for Your Portfolio
CNCR
zacks.com10 October 2024

Low-priced ETFs could be attractive for investors as these enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.

5 Top-Ranked ETFs to Buy at a Bargain
5 Top-Ranked ETFs to Buy at a Bargain
5 Top-Ranked ETFs to Buy at a Bargain
CNCR
zacks.com07 August 2024

After a three-day rout, Wall Street staged a solid comeback as investors bought beaten-down stocks and recession fears eased. To tap the beaten-down prices, we have highlighted five ETFs from different corners that have declined over the past week and have a solid Zacks ETF Rank.

5 Market-Beating Sector ETFs of Q1
5 Market-Beating Sector ETFs of Q1
5 Market-Beating Sector ETFs of Q1
CNCR
Zacks Investment Research27 March 2024

Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.

5 Sector ETFs Beating the Market Halfway Through Q1
5 Sector ETFs Beating the Market Halfway Through Q1
5 Sector ETFs Beating the Market Halfway Through Q1
CNCR
Zacks Investment Research12 February 2024

A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.

Range Debuts 4 Energy-Related ETFs
Range Debuts 4 Energy-Related ETFs
Range Debuts 4 Energy-Related ETFs
CNCR
ETF Trends24 January 2024

Range ETFs expanded its lineup on Wednesday to include four energy-related ETFs. They cover the coal, natural gas, oil services, and nuclear industries.

Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace
Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace
Last Week in ETFs: 15 Launches, Closures Continue Rapid Pace
CNCR
ETF Trends26 June 2023

It was a busy week for ETF launches and closures. A total of 15 ETFs launched during the week shortened by the Juneteenth holiday, defying the typically slow launch count for weeks surrounding three-day weekends.

FAQ

  • What is CNCR ETF?
  • Does CNCR pay dividends?
  • What stocks are in CNCR ETF?
  • What is the current assets under management for CNCR?
  • What is CNCR average volume?
  • What is CNCR expense ratio?
  • What is CNCR inception date?

What is CNCR ETF?

The CNCR ETF is an exchange-traded fund that focuses on companies involved in cancer research and treatment. It aims to provide investors with exposure to the growing healthcare sector, particularly in oncology, by investing in firms developing innovative therapies and technologies for cancer care.

Does CNCR pay dividends?

Yes, the Range Cancer Therapeutics Index ETF does pays dividends, with the most recent payment being $1.85 per share. The last ex-dividend date was on 29 December 2021, and the next ex-dividend date has not been announced yet

What stocks are in CNCR ETF?

As of today, Range Cancer Therapeutics Index ETF inlcudes 31 holdings, with 29 of them being companies from 8 different countries and 1 sectors. The most weighted holdings are Instil Bio (3.59%), Replimune (3.54%) and Iovance Biotherapeutics (3.47%)

What is the current assets under management for CNCR?

Assets under management of Range Cancer Therapeutics Index ETF is $13 M

What is CNCR average volume?

Average volume of Range Cancer Therapeutics Index ETF is $7482

What is CNCR expense ratio?

Expense ratio of Range Cancer Therapeutics Index ETF is 0.79%

What is CNCR inception date?

Inception date of Range Cancer Therapeutics Index ETF is 14 October 2015